What is Noxopharm?
Noxopharm Limited is an innovative Australian biotech company dedicated to the discovery and development of novel therapeutics for oncology and autoimmune diseases, alongside advancements in mRNA vaccine technology. The company leverages its proprietary Chroma and Sofra technology platforms to build a robust pipeline of drug candidates. Its lead clinical asset, Veyonda, is currently undergoing trials aimed at improving cancer treatment outcomes, particularly when used in conjunction with immunotherapy. Noxopharm's commitment lies in addressing critical unmet medical needs through pioneering research and development.
How much funding has Noxopharm raised?
Noxopharm has raised a total of $23.1M across 2 funding rounds:
Debt
$15M
Share Placement
$8.1M
Debt (2019): $15M, investors not publicly disclosed
Share Placement (2020): $8.1M, investors not publicly disclosed
What's next for Noxopharm?
The recent major strategic investment provides Noxopharm with substantial backing to advance its clinical pipeline and technology platforms. This infusion of capital is expected to accelerate the development of Veyonda and further research into its oncology and autoimmune disease programs. The company's focus on enhancing mRNA vaccines also positions it to capitalize on emerging trends in vaccine technology. With this strategic financing, Noxopharm is poised to strengthen its market position and pursue its mission of delivering innovative treatments for significant global health challenges.
See full Noxopharm company page
